COX-2 inhibitors: increased risk of CV events?

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2001年 / 867卷 / 1期

关键词：

Celecoxib; Naproxen; Rofecoxib; Nabumetone; Adverse Event Reporting System;

D O I：

10.2165/00128415-200108670-00001

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[1] Proposed risk of CV events with COX-2 inhibitors debated
Reactions Weekly, 2002, 883 (1) : 6 - 7
[2] COX-2 inhibitors: lower GI bleeding risk but population risk increased?
Reactions Weekly, 2004, 1002 (1) : 3 - 3
[3] COX-2 Inhibitors and Cardiovascular Risk
Cannon, Christopher P.
Cannon, Paul J.
SCIENCE, 2012, 336 (6087) : 1386 - 1387
[4] Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?Linking Pharmacology with Pharmacoepidemiology
David W.J. Clark
Deborah Layton
Saad A.W. Shakir
Drug Safety, 2004, 27 : 427 - 456
[5] Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events
Mukherjee, D
BIOCHEMICAL PHARMACOLOGY, 2002, 63 (05) : 817 - 821
[6] Adverse drug events involving COX-2 inhibitors
Verrico, MM
Weber, RJ
McKaveney, TP
Ansani, NT
Towers, AL
ANNALS OF PHARMACOTHERAPY, 2003, 37 (09) : 1203 - 1213
[7] Perception of risk: the state of COX-2 selective inhibitors.
Simon L.S.
Strand V.
Current Rheumatology Reports, 2005, 7 (3) : 163 - 166
[8] COX-2 inhibitors in rheumatoid arthritis
Sundy J.S.
Current Rheumatology Reports, 2001, 3 (1) : 86 - 91
[9] COX-1 and COX-2 inhibitors
Hawkey, CJ
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (05) : 801 - 820
[10] Contest between the COX-2 inhibitors continues
Reactions Weekly, 2000, 815 (1) : 3 - 4

← 1 2 3 4 5 →